Evidence map›Paper›PMID 41559809›Full record

ArticleActa neuropathologica communications2026

Overexpression of bank vole PrP(I109) in mice induces a spontaneous atypical prion disease with sex-dependent onset, early NfL elevation, and universal prion strain permissiveness.

Hasier Eraña, Enric Vidal, Natalia Fernández-Borges, Jorge M Charco, Carlos M Díaz-Domínguez, Cristina Sampedro-Torres-Quevedo, Maitena San-Juan-Ansoleaga, Eva Fernández-Muñoz, Josu Galarza-Ahumada, Miguel Ángel Pérez-Castro and 22 more

Abstract read
In one paragraph

Article in Acta neuropathologica communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Hasier ErañaCenter for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
Enric VidalIRTA, Programa de Sanitat Animal, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra, Catalonia, Spain.
Natalia Fernández-BorgesCentro de Investigación en Sanidad Animal (CISA), Consejo Superior de Investigaciones Científicas (CSIC), Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Valdeolmos, Madrid, Spain.
Jorge M CharcoCenter for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
Carlos M Díaz-DomínguezCenter for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
Cristina Sampedro-Torres-QuevedoCenter for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
Maitena San-Juan-AnsoleagaCenter for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
Eva Fernández-MuñozCenter for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
Josu Galarza-AhumadaCenter for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
Miguel Ángel Pérez-CastroCenter for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
Nuno Gonçalves-AnjoCenter for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
Patricia PiñeiroCenter for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
Laura PirisinuDepartment of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanita, Rome, Italy.
Michele Angelo Di BariDepartment of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanita, Rome, Italy.
Samanta GilerIRTA, Programa de Sanitat Animal, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra, Catalonia, Spain.
Ilaria RaimondiDepartment of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Juan Carlos EspinosaCentro de Investigación en Sanidad Animal (CISA), Consejo Superior de Investigaciones Científicas (CSIC), Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Valdeolmos, Madrid, Spain.
Ilaria VanniDepartment of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanita, Rome, Italy.
Claudia D'AgostinoDepartment of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanita, Rome, Italy.
Juan Rodríguez-CuestaCenter for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
Laura PasettoDepartment of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Valentina BonettoDepartment of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Nora González-MartínInstitute for Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, University of Salamanca, Spanish National Research Council (CSIC), Salamanca, Spain.
Susana TeijeiraGrupo de Enfermedades Raras y Medicina Pediátrica, Instituto de Investigación Sanitaria Galicia Sur (IISGS), Vigo, Spain.
Wen-Quan ZouInstitute of Neurology, Jiangxi Academy of Clinical Medical Sciences, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Mariví GeijoAnimal Health Department, NEIKER-Basque Institute for Agricultural Research and Development, Basque Research and Technology Alliance (BRTA), Derio, Spain.
Juan María TorresCentro de Investigación en Sanidad Animal (CISA), Consejo Superior de Investigaciones Científicas (CSIC), Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Valdeolmos, Madrid, Spain.
Roberto ChiesaDepartment of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Manuel A Sánchez-MartínInstitute for Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, University of Salamanca, Spanish National Research Council (CSIC), Salamanca, Spain.
Romolo NonnoDepartment of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanita, Rome, Italy.
Jesús R RequenaCIMUS Biomedical Research Institute, University of Santiago de Compostela-IDIS, Santiago, Spain.
Joaquín CastillaCenter for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain. jcastilla@cicbiogune.es.

Funding

Agencia Estatal de Investigación PID2020-117465GB-I00Agencia Estatal de Investigación PID2021-1222010B-C22Agencia Estatal de Investigación PID2023-146146NB-I00Agencia Estatal de Investigación PID2024-160022OB-I00EU Joint Programme - Neurodegenerative Disease Research JPND-2021-650-130European Regional Development Fund EFA031/01 NEURO-COOPFundación Tatiana Pérez de Guzmán el Bueno BN661-FTPGB-2023Instituto de Salud Carlos III PT23/00123
6 · The paper itself

Abstract

Transgenic mice overexpressing bank vole prion protein with the isoleucine 109 polymorphism, TgVole(I109)4x, develop spontaneous neurodegenerative disease with sex-dependent onset, averaging 170 days in females and 200 days in males at terminal stage. The clinical and pathological features closely resemble Gerstmann-Sträussler-Scheinker syndrome (GSS), with characteristic ataxia, dysmetria, kyphosis, and prominent PrP plaques. Biochemical analysis reveals an atypical prion protein banding pattern with a distinctive low molecular weight band (7-10 kDa) following proteinase K digestion, similar to other atypical prion diseases such as small ruminants atypical scrapie (AS). Importantly, these spontaneously generated prions are highly infectious when passaged to mice expressing the same I109 polymorphism as well as to wild bank voles carrying the I109 polymorphism, but not to models expressing the methionine variant at this position, demonstrating the critical role of this specific polymorphism in atypical prion propagation. Temporal analysis reveals that infectious prions emerge significantly (2-3 months) before clinical signs appear, offering important insights into the pre-clinical phase of prion diseases. Serum neurofilament light chain levels increase significantly at 80 days of age, approximately 100 days before clinical onset, providing a wide therapeutic window with a reliable biomarker. The TgVole(I109)4× model exhibits extraordinary versatility in propagating diverse prion strains, showing remarkable susceptibility to atypical prions (including GSS and AS) with exceptionally short incubation periods, while maintaining the ability to efficiently propagate classical and recombinant prion strains. We present here a thoroughly characterized transgenic mouse model that spontaneously develops an atypical, bona fide prion disease with sex-related differences in disease onset. This model offers valuable insights into spontaneous and atypical prionopathies while demonstrating exceptional versatility for studying diverse prion strains and potential utility for evaluating therapeutic interventions when used with appropriate study designs that account for individual variability.

Indexed as

Neurofilament ProteinsPrion DiseasesPrion ProteinsPrionsSex CharacteristicsAnimalsArvicolinaeBrainDisease Models, AnimalFemaleGerstmann-Straussler-Scheinker DiseaseMaleMiceMice, TransgenicNeurofilament ProteinsPrion ProteinsPrionsAtypical prionsBank voleEarly diagnostic biomarkersI109 polymorphismNeurofilament light chain (NfL)Prion diseasesPrion transmissionSpontaneous neurodegenerationTransgenic mice

Identifiers

PMID41559809
PMCPMC12903601

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.